EMA Authorised: Emtricitabine/Tenofovir disoproxil Krka (emtricitabine;tenofovir disoproxil succinate) — KRKA, d.d., Novo mesto

View source ↗

Summary

The EMA authorised the fixed-dose combination emtricitabine/tenofovir disoproxil for HIV infections, marketed by KRKA, d.d., Novo mesto.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Emtricitabine/Tenofovir disoproxil Krka (emtricitabine; tenofovir disoproxil succinate)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: KRKA, d.d., Novo mesto. Decision date: 31/01/2025